These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2280989)

  • 21. [Studies on the persistence of immunity 14-15 years after vaccination with a live measles vaccine].
    Zhonghua Yi Xue Za Zhi; 1989 Jul; 69(7):389-91. PubMed ID: 2598095
    [No Abstract]   [Full Text] [Related]  

  • 22. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine].
    Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N
    Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measles, measles vaccination, and risk of subacute sclerosing panencephalitis (SSPE).
    Zilber N; Rannon L; Alter M; Kahana E
    Neurology; 1983 Dec; 33(12):1558-64. PubMed ID: 6685828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measles: summary of worldwide impact.
    Assaad F
    Rev Infect Dis; 1983; 5(3):452-9. PubMed ID: 6878998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SSPE (subacute sclerosing panencephalitis): Is measles vaccination promotive or preventive?
    McDonald R
    Clin Pediatr (Phila); 1977 Feb; 16(2):124-7. PubMed ID: 832436
    [No Abstract]   [Full Text] [Related]  

  • 26. Measles vaccination policy.
    Williams BG; Cutts FT; Dye C
    Epidemiol Infect; 1995 Dec; 115(3):603-21. PubMed ID: 8557092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination.
    Dilraj A; Sukhoo R; Cutts FT; Bennett JV
    Vaccine; 2007 May; 25(21):4170-4. PubMed ID: 17408818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency, serodiagnosis and epidemiological features of subacute sclerosing panencephalitis (SSPE) and epidemiology and vaccination policy for measles in the Federal Republic of Germany (FRG).
    Enders-Ruckle G
    Dev Biol Stand; 1978; 41():195-207. PubMed ID: 381072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Waning of vaccine-induced immunity: is it a problem in Africa?
    Aaby P; Cisse B; Simondon F; Samb B; Soumaré M; Whittle H
    Am J Epidemiol; 1999 Feb; 149(4):304-5. PubMed ID: 10025471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis.
    Low N; Kraemer S; Schneider M; Restrepo AM
    Vaccine; 2008 Jan; 26(3):383-98. PubMed ID: 18082295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Complications of measles and antimeasles vaccination].
    Reinert P; Lemerle S; Kohout G; Bernaudin F
    Ann Pediatr (Paris); 1984 Jun; 31(6):477-80. PubMed ID: 6147112
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevention of measles in Israel: short- and long-term intervention strategies.
    Tulchinsky TH
    Isr J Med Sci; 1991 Jan; 27(1):22-9. PubMed ID: 1995496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical measles in adolescent siblings 16 years after killed measles virus vaccine.
    Fulginiti VA; Helfer RE
    JAMA; 1980 Aug 22-29; 244(8):804-6. PubMed ID: 7392190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measles virus antibody responses in children randomly assigned to receive standard-titer edmonston-zagreb measles vaccine at 4.5 and 9 months of age, 9 months of age, or 9 and 18 months of age.
    Martins C; Garly ML; Bale C; Rodrigues A; Njie-Jobe J; Benn CS; Whittle H; Aaby P
    J Infect Dis; 2014 Sep; 210(5):693-700. PubMed ID: 24688075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subacute sclerosing panencephalitis after passive immunization and natural measles infection: role of antibody in persistence of measles virus.
    Rammohan KW; McFarland HF; McFarlin DE
    Neurology; 1982 Apr; 32(4):390-4. PubMed ID: 7199661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine.
    Garly ML; Balé C; Martins CL; Monteiro M; George E; Kidd M; Dias F; Aaby P; Whittle HC
    Vaccine; 2001 Feb; 19(15-16):1951-9. PubMed ID: 11228365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Measles in France].
    Antona D; Baudon C; Freymuth F; Lamy M; Maine C; Parent du Chatelet I; Lévy-Bruhl D
    Med Sci (Paris); 2012 Nov; 28(11):1003-7. PubMed ID: 23171908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune status following measles vaccination in infants and evaluation for the need of revaccination.
    Dutta AK; Singhal PK; Khare S; Kumari S; Mathur R; Mullick DN
    Indian Pediatr; 1989 Aug; 26(8):765-72. PubMed ID: 2620977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization of young infants with Edmonston-Zagreb measles vaccine.
    Markowitz LE; Bernier RH
    Pediatr Infect Dis J; 1987 Sep; 6(9):809-12. PubMed ID: 3313247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subacute sclerosing panencephalitis in Iran.
    Shafyi A; Lotfi J; Mirchamsy H
    Kitasato Arch Exp Med; 1984 Dec; 57(4):267-71. PubMed ID: 6543890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.